We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

226 hedge funds and large institutions have $4.34B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 15

325% more call options, than puts

Call options by funds: $160M | Put options by funds: $37.7M

122% more capital invested

Capital invested by funds: $1.95B → $4.34B (+$2.39B)

60% more funds holding in top 10

Funds holding in top 10: 1016 (+6)

29% more funds holding

Funds holding: 175226 (+51)

22% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 63

Holders
226
Holders Change
+51
Holders Change %
+29.14%
% of All Funds
4.63%
Holding in Top 10
16
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+60%
% of All Funds
0.33%
New
67
Increased
77
Reduced
63
Closed
15
Calls
$160M
Puts
$37.7M
Net Calls
+$122M
Net Calls Change
+$22M
Name Holding Trade Value Shares
Change
Change in
Stake
PAMU
51
Pictet Asset Management (UK)
United Kingdom
$15M +$3.11M +58,403 +40%
RSCM
52
Rock Springs Capital Management
Maryland
$14.9M +$203K +3,817 +2%
CWG
53
C WorldWide Group
Denmark
$14.8M -$5.85M -110,000 -35%
Adage Capital Partners
54
Adage Capital Partners
Massachusetts
$14.6M +$161K +3,025 +2%
CS
55
Candriam SCA
Luxembourg
$12.6M -$851K -16,000 -8%
FCM
56
Frontier Capital Management
Massachusetts
$12.3M -$1.62M -30,367 -15%
Thrivent Financial for Lutherans
57
Thrivent Financial for Lutherans
Minnesota
$12.1M +$3.45M +64,811 +64%
BAMCO Inc
58
BAMCO Inc
New York
$11.1M
American Century Companies
59
American Century Companies
Missouri
$11M +$3.96M +74,466 +98%
ACM
60
Atika Capital Management
New York
$10.6M +$3.81M +71,500 +97%
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
$9.06M -$796K -14,957 -11%
BC
62
Blackcrane Capital
Washington
$8.98M -$7.72M -145,003 -54%
GCM
63
Glenview Capital Management
New York
$8.8M +$6.4M +120,332 New
Two Sigma Advisers
64
Two Sigma Advisers
New York
$8.53M -$2.74M -51,500 -31%
State of Wisconsin Investment Board
65
State of Wisconsin Investment Board
Wisconsin
$8.47M -$3.39M -63,756 -36%
OM
66
Opaleye Management
Massachusetts
$8.36M +$6.09M +114,350 New
Parallax Volatility Advisers
67
Parallax Volatility Advisers
California
$8.3M +$6M +112,697 +13,879%
Bank of America
68
Bank of America
North Carolina
$8.2M +$34.9K +656 +0.6%
Swiss National Bank
69
Swiss National Bank
Switzerland
$8.09M +$1.31M +24,600 +29%
PAM
70
Panagora Asset Management
Massachusetts
$7.63M +$137K +2,568 +3%
GGHC
71
Gilder Gagnon Howe & Co
New York
$7.48M +$10.3K +193 +0.2%
GKIM
72
GW&K Investment Management
Massachusetts
$7.02M -$1.92M -35,996 -27%
California Public Employees Retirement System
73
California Public Employees Retirement System
California
$7.01M +$380K +7,140 +8%
Federated Hermes
74
Federated Hermes
Pennsylvania
$6.69M +$4.87M +91,498 New
CM
75
Castleark Management
Illinois
$6.61M +$4.81M +90,450 New

BHVN Hedge Fund Activity: Q2 2020 in Review

226 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2020, worth a combined $4.34B — up 122% from $1.95B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new BHVN positions and 15 closed out — a net gain of 52 holders — while 77 added to existing stakes and 63 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $52.2M. The largest seller was Wellington Management Group, cutting an estimated $55.1M.

  • 226 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2020, up from 175 in Q1 2020.
  • Funds reported $4.34B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2020, up 122% quarter-over-quarter.
  • 67 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2020 and 15 closed out, a net change of +52 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2020 was Tang Capital Management, an estimated $52.2M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2020 was Wellington Management Group, an estimated $55.1M sold.

Based on aggregated 13F filings for Q2 2020.